Figure 2.
Immune cell dynamics using flow cytometry before and after daratumumab-based therapy.
Rapid downregulation of NK cells, B cells, Bregs, and Tregs can be noted after 4 weeks of daratumumab-based therapy. Meanwhile, the proportion of T cells is increased, with a higher increase of CD8+ compared with CD4+ T cells.
Bregs, regulatory B cells; Tregs, regulatory T cells; NK, natural killer.